Cargando…

Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) are standard treatments for advanced non-small cell lung cancer (NSCLC); however, evidence regarding their relative efficacy and safety is lacking. This study compared the efficacy and safety of all currently available ICI treatments in patients with a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yan, Liang, Xueyan, Li, Huijuan, Chen, Xiaoyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Meta Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508436/ https://www.ncbi.nlm.nih.gov/pubmed/37596898 http://dx.doi.org/10.1097/CM9.0000000000002750

Ejemplares similares

Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis
por: Li, Huijuan, et al.
Publicado: (2023)

The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis
por: Huang, Guanghong, et al.
Publicado: (2017)

Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis
por: Hu, Hao, et al.
Publicado: (2018)

Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis
por: Qian, Da, et al.
Publicado: (2023)

Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
por: Yang, Li, et al.
Publicado: (2020)

Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors
por: Li, Nijiao, et al.
Publicado: (2023)

PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment
por: Su, Qiang, et al.
Publicado: (2017)

Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
por: Roviello, Giandomenico, et al.
Publicado: (2019)

The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review
por: Swildens, Kyra X, et al.
Publicado: (2022)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis
por: Cavanna, Luigi, et al.
Publicado: (2019)

Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis
por: Alanazi, Abdullah, et al.
Publicado: (2020)

Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis
por: Wenfan, Fu, et al.
Publicado: (2023)

Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis
por: Zou, Yutian, et al.
Publicado: (2020)

The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis
por: Han, Shiqian, et al.
Publicado: (2017)

Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis
por: Sun, Jinping, et al.
Publicado: (2017)

Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy
por: Wu, Di, et al.
Publicado: (2017)

Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review
por: Kim, Bum Jun, et al.
Publicado: (2017)

Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer
por: Jiang, Qi, et al.
Publicado: (2017)

Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis
por: Pei, Wen-Guang, et al.
Publicado: (2023)

Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2017)

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%
por: Freemantle, Nick, et al.
Publicado: (2022)

Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma
por: Petersohn, Svenja, et al.
Publicado: (2023)

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
por: Carretero-González, Alberto, et al.
Publicado: (2018)

Assessment on the Efficacy and Safety of Aidi Injection Combined with Vinorelbine and Cisplatin for Treatment of Advanced Nonsmall Cell Lung Cancer
por: Zhao, Hua-Ye, et al.
Publicado: (2016)

Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer
por: Li, Fei, et al.
Publicado: (2017)

Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
por: Chen, Baoqing, et al.
Publicado: (2022)

MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis
por: Loo, Jing Hong, et al.
Publicado: (2022)

Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis
por: Lu, Wenjie, et al.
Publicado: (2022)

The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis
por: Sun, Xin-Fang, et al.
Publicado: (2017)

Safety and Efficacy of Tranexamic Acid in Total Knee Arthroplasty
por: Yu, Xiao, et al.
Publicado: (2015)

Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis
por: Zhang, Shuo, et al.
Publicado: (2021)

Efficacy and Safety of Antiplatelet Therapy Plus Xa Factor Inhibitors in Patients with Coronary Heart Disease: A Meta-Analysis
por: Chen, Hongsen, et al.
Publicado: (2019)

Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis
por: Nso, Nso, et al.
Publicado: (2020)

Efficacy and safety of vericiguat in heart failure: a meta-analysis
por: Ma, Jianhua, et al.
Publicado: (2023)

Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis
por: Lan, Bo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gsifeha7lugkji6mv1s3ll02jk